Navigation Links
Inivata Highlights its InVisionTM ctDNA Assay for Broad Molecular Profiling and Presentation of NSCLC data at ASCO Annual Meeting 2016
Date:6/1/2016

RESEARCH TRIANGLE PARK, North Carolina and CAMBRIDGE, England, June 1, 2016 /PRNewswire/ --

 

Inivata, a global clinical cancer genomics company employing the precision of circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, will introduce its proprietary InVisionTM ctDNA assay for broad molecular profiling during the 2016 Annual Meeting of the American Society of Clinical Oncology ('ASCO') at McCormick Place in Chicago, Illinois, June 3-7, 2016.

The InVisionTM assay utilizes the innovative application of Inivata's proprietary enhanced tagged-amplicon sequencing (eTAm-SeqTM) platform for genomic analysis, which was developed by Inivata on the basis of the TAm-SeqTM technology from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge.  InVisionTM was developed to serve as a reliable, multi-gene, support tool for oncologists to accurately translate genomic alterations into actionable information to inform clinical decision making and improve cancer treatment planning for the patient. Commercial availability of the InVisionTM assay will be the subject of a future announcement.

At ASCO, clinical data from the InVisionTM assay in non-small cell lung cancer is being co-presented with Institut Gustave Roussy. The following abstract will be presented during the poster session:


Abstract Title: Evaluation of liquid biopsies for molecular profiling and monitoring in non-small cell lung cancer (NSCLC) patients. (Abstract #: 11533)
Location: Poster Session: Tumor Biology, Hall A, Board Number 230
Date/Time: June 6th, 1:00 - 4:30pm
Presenter: Jordi Remon, MD
Author affiliations: Institut Gustave Roussy and Inivata

Inivata's representatives will also be exhibiting and providing further details on the impending commercial launch of the InVisionTM assay at the ASCO annual meeting booth number 6161. To arrange an interview or meeting please contact us via info@inivata.com

About Inivata

Inivata, a clinical cancer genomics company, is employing the precision of ctDNA analysis to improve personalised healthcare in oncology. Using a simple blood test, circulating tumour DNA (ctDNA) analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. Inivata's proprietary technology is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. Inivata's InVision[TM] ctDNA assay provides a highly sensitive analysis of a strategically selected gene panel to identify actionable mutations for oncologists to treat their patients optimally. For more information and a full listing of investors, please go to http://www.inivata.com. Follow us on twitter @Inivata

About ASCO Annual Meeting 2016

The American Society of Clinical Oncology ('ASCO') Annual Meeting brings together 30,000 oncology professionals from around the world. Educational sessions feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Science sessions present the latest ground-breaking research in oral and poster format.

The theme for ASCO 2016 is Collective Wisdom: The Future of Patient-Centered Care and Research.

Company Contact:
Liz Macfadyen
Email: liz.macfadyen@inivata.com
Phone: +44(0)7739462323

Media Contacts
Consilium Strategic Communications
Chris Gardner/Laura Thornton
Phone: +44(0)20-3709-5700
inivata@consilium-comms.com

 



'/>"/>
SOURCE Inivata
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Inivata Announces Appointment of Jeffrey Buchalter as Chairman
2. Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests
3. New Research Highlights Value of Protein Test in Mesothelioma Prognosis, According to Surviving Mesothelioma
4. Listeria Food Recall Highlights Need for Faster Bio Threat Detection
5. ReachMD Educational Program Highlights Asthma and Allergy Connections
6. Synthetic Biologics Reports 2015 Year End Operational Highlights and Financial Results
7. ‘Dying in America: Conversations About Care at the End of Life’ Launches on ReachMD, Highlights IOM’s Consensus Report on the Controversies and Complexities of Care
8. Proove Biosciences Highlights Personalized Medicine Technology as an Approach to Reduce Prescription Drug Abuse
9. Pittcon 2016 Announces Exposition Highlights
10. New PDI Visual Resource Highlights How Proper Disinfection Can Reduce Central Line-associated Bloodstream Infections (CLABSIs)
11. MEI Pharma Highlights New Data from Phase II Clinical Studies of Pracinostat in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2018)... ... November 05, 2018 , ... 2Blades has completed a non-exclusive ... effector code technology for applications in advancing research in epigenetic technology. , ... discovery in 2009, the efficacy of TAL effector-based DNA targeting has been established ...
(Date:10/31/2018)... (PRWEB) , ... October 30, 2018 , ... Rooam ... will launch operations in Chicago this winter. After its acquisition of the Tally payment ... complete transactions and set default tips, Rooam will grow its market share and increase ...
(Date:10/31/2018)... ... October 30, 2018 , ... The assessment ... very important aspect of experimental biology. Reproducibility of cell-based assays is one of ... choosing the appropriate assay type, there are many more factors to be considered ...
(Date:10/25/2018)... ... October 24, 2018 , ... To prepare for radiological and nuclear emergencies, ... Argentum Medical, LLC to repurpose its commercial Silverlon ® technology for ... privately held company has been awarded a three-year, $8.4 million contract with the Biomedical ...
Breaking Biology Technology:
(Date:11/6/2018)... ... November 06, 2018 , ... ... announced that Sartorius Stedim Cellca GmbH, a subsidiary of Sartorius Stedim Biotech (SSB) ... production, has licensed the Genedata Bioprocess ® enterprise platform to be used ...
(Date:11/3/2018)... ... November 01, 2018 , ... Karius , the ... next-generation sequencing to study human pathogens in pediatric patients. One grant of up to ... Karius cell-free DNA test for infectious diseases. In addition to the funding, Karius will ...
(Date:11/3/2018)... LINDA, Calif. (PRWEB) , ... November 01, 2018 ... ... dentistry concerned with the morphology, physiology and pathology of the human dental pulp ... visualizing the anatomy of the human teeth, but, over the last decade, non-destructive, ...
Breaking Biology News(10 mins):